Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off

Retrieved on: 2024-03-21 11:44:54

Tags for this article:

Click the tags to see associated articles and topics

Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off. View article details on HISWAI: https://www.biopharmadive.com/news/mirador-therapeutics-prometheus-arch-launch/710904/

Summary

Mark McKenna's new biopharma venture, Mirador Therapeutics, follows his previous work at Prometheus Biosciences and focuses on precision therapies for autoimmune diseases, supported by a significant Series A funding that includes Sanofi, a CAC 40 company.

Article found on: www.biopharmadive.com

View Original Article